Posts

Biotech's IPO Tide Turning Amid M&A Surge

Kailera CEO Confident Before Record-Breaking $625M Obesity Biotech IPO

Kailera Therapeutics Files for Nasdaq IPO to Fund Obesity Drug Pipeline Licensed from China Partner